AnalystsInsight

Dev Prasad (Lucid Capital): Analyst Track Record and Price‑Target Accuracy

How often Dev Prasad’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 28 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

#984 rank (was #811)+2 new ratings (GNLX, FTH)+2 stocks newly covered4.6★ rating (was 4.7★)

Key takeaways

  • Dev Prasad ranks #870 of 1,000 analysts in Exent’s scoring (4.6★).
  • 33.3% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 210 days; 83.3% of calls were up 12 months later.
  • Most‑covered stocks: PVLA, IFRX, QNRX, ABOS.
  • Free on Exent: Dev Prasad’s full record, with ratings 3 days after publication.

Dev Prasad’s track record at a glance

Dev Prasad of Lucid Capital ranks #870 of the 1,000 analysts Exent scores, with a 4.6★ rating and a focus on healthcare. Over a 7‑year lookback, 33.3% of Dev’s price targets were reached, 19.1 points below the 52.4% average across all analysts.

MetricDev PrasadAll analysts
Price‑target hit rate33.3%52.4%
Median days to hit target210 days91 days
Calls up after 12 months83.3%64.0%
Median 12‑month return of calls+88.9%+13.4%
Hit rate, last 2 years33.3%—
Average worst drop after a call−40.7%—
Ratings in the sample28—
Stocks covered14—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetDev Prasad
Under 30 days0.0%
30–90 days25.0%
90–180 days25.0%
Over 180 days50.0%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Dev Prasad covers most

StockRatings in the sample
PVLA5
IFRX3
QNRX2
ABOS2
VRCA2
TSX-MDNA2
ATYR2
CUE2

In the past year Dev’s ratings were 100% Buy, 0% Hold and 0% Sell.

Dev Prasad’s latest ratings

DateStockActionRatingPrice target
Sep 16, 2026GNLXInitiated Coverage: BuyBuy$18.00
Sep 14, 2026FTHInitiated Coverage: BuyBuy$59.00
Sep 8, 2026ANLInitiated Coverage: BuyBuy$49.00
Aug 20, 2026ELOXInitiated Coverage: BuyBuy$38.00
Jul 27, 2026PLYXInitiated Coverage: BuyBuy$7.00
May 4, 2026QNRXInitiated CoverageBuy$30.00
May 4, 2026QNRXInitiated Coverage: BuyBuy$30.00
Dec 17, 2025ABOSInitiated Coverage: BuyBuy$6.00
Dec 17, 2025ABOSInitiated CoverageBuy$6.00
Dec 15, 2025PVLAReiterated: BuyBuy$212.00
Dec 15, 2025PVLAMaintained: BuyBuy$212.00
Dec 15, 2025PVLAMaintainedBuy$212.00
  • Sep 16, 2026
    Stock
    GNLX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $18.00
  • Sep 14, 2026
    Stock
    FTH
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $59.00
  • Sep 8, 2026
    Stock
    ANL
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $49.00
  • Aug 20, 2026
    Stock
    ELOX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $38.00
  • Jul 27, 2026
    Stock
    PLYX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $7.00
  • May 4, 2026
    Stock
    QNRX
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $30.00
  • May 4, 2026
    Stock
    QNRX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $30.00
  • Dec 17, 2025
    Stock
    ABOS
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $6.00
  • Dec 17, 2025
    Stock
    ABOS
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $6.00
  • Dec 15, 2025
    Stock
    PVLA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $212.00
  • Dec 15, 2025
    Stock
    PVLA
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $212.00
  • Dec 15, 2025
    Stock
    PVLA
    Action
    Maintained
    Rating
    Buy
    Price target
    $212.00

Dev’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Dev Prasad’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Dev Prasad ranks #870 of 1,000 with a 4.6★ rating. 33.3% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 83.3% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Dev Prasad’s success rate is 50.0% by the ranking source and 33.3% by Exent’s price-target hit-rate backtest, with a median of 210 days to reach a target.

Dev Prasad (Lucid Capital) covers 14 stocks, mostly in healthcare. The most frequently rated are PVLA, IFRX, QNRX, ABOS, VRCA.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.